Current stock page

Stock Analysis

Kura Oncology, Inc. (KURA) Stock Analysis

Kura Oncology, Inc. (KURA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

KURA Stock Analysis Summary

Kura Oncology, Inc. (KURA) currently has an AIQ Score of 47/100, indicating a bearish setup. Value is the strongest factor at 70/100. Risk is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

KURA at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$7.77
AIQ Score47/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$697.88M
P/E Ratio (TTM)-2.35
Forward P/E—
EPS (Q3 FY2026)-$0.78
Revenue (Q3 FY2026)$22.84M
Dividend Yield (TTM)0.00%
Beta1.33
Volume2.23M
52-week range$6.75-$13.90
RSI 1437.1
50-Day SMA$10.17
200-Day SMA$9.77
Analyst Price Target$24.00
Next EarningsMar 4, 2027
As of Nov 13, 2026 · Market close

KURAKura Oncology, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

BearishEdge 4/10
$7.77+$0.34 (+4.58%)

Latest quote

  • Momentum
    40
  • Value
    70
  • Quality
    45
  • Risk resilience
    39
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

KURA Stock Analysis Summary

Kura Oncology, Inc. (KURA) currently has an AIQ Score of 47/100, indicating a bearish setup. Value is the strongest factor at 70/100. Risk resilience is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, KURA has AIQ Score of 47/100 with Value base of 70/100 and fading Risk resilience at 39/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Value (70/100) leads while Risk resilience (39/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 4.58% stock move · KURA classified in Biotechnology.

Current Evidence

BearishKURA is in a bearish AIQ regime; Value is the strongest visible factor at 70/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is KURA Bullish or Bearish Right Now?

KURA currently has a bearish overall setup. Value is the strongest factor at 70/100, while Risk Resilience is weakest at 39/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +208.88% upside from the latest quote.
Bear Case
  • - Momentum is weak at 40/100.
  • - Risk Resilience is weak at 39/100.
  • - Price is -20.51% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (35 vs 3).

Current Consensus

KURA's Technical Analysis Consensus is currently Strong Sell, with 3 buy, 8 neutral, and 35 sell votes. KURA's 14-day RSI is 37.1, which places the stock in a weaker momentum range. KURA's beta is 1.33, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in KURA?

The largest recent change in KURA is Momentum moving down by 23.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
-8.0
Momentum
-23.0
Quality
+0.0
Risk
+0.0

What Would Change the KURA Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

KURA Decision Framework

Public evidence layers, setup checks, and risk context for Kura Oncology, Inc..

Kura Oncology, Inc. (KURA) Stock Analysis

Kura Oncology, Inc. has an AIQ Score of 47/100 in a Bearish regime. Value is strongest at 70/100. Beta is 1.33, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextKURA is in a Bearish AIQ regime with score 47/100.
Signal ConflictThe primary conflict is that value leads at 70/100 while risk lags at 39/100.
Factor EvidenceMomentum 40/100 · Value 70/100 · Quality 45/100 · Risk 39/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 70/100.

TimingFail

Momentum is 40/100 and RSI (14) is 37.1.

Regime fitFail

KURA is in a Bearish regime at 47/100.

Risk controlFail

Risk factor is 39/100 with beta 1.33 and annual volatility 63.01%.

ConflictWait

Current conflict: value leads at 70/100 while risk lags at 39/100.

AIQ Score
47/100
Price
$7.77
Beta
1.33
RSI (14)
37.1

KURA Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

KURA Fundamentals

KURA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$22.84M
Net income
-$70.22M
Free cash flow
-$54.89M
View full KURA fundamental analysis

KURA Technical Analysis

KURA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
37.1
Price vs SMA-50
-23.59%
View full KURA technical analysis

KURA Stock Catalysts

Track KURA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 4, 2027
Analyst target
$24.00
News items
3
View KURA earnings and stock catalysts

KURA Dividend Analysis

KURA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View KURA dividend history and analysis

KURA Financial Data

KURA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$22.84M
EPS
-$0.78
Periods
8
View KURA financials

KURA Risk Analysis

KURA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.33
Risk score
39/100
1Y volatility
63.01%
View KURA risk analysis

KURA Stock News

KURA stock news, market tone, recent headlines, and catalyst context.

News items
3
Updated
Nov 15, 2026
Sentiment
—
Read KURA stock news

KURA vs Biotechnology Peers

Current peer cohort: KURA · KYMR · LGND · MAZE · MBX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
KURA
Current stock
47/10070/10040/10039/100-0.2563.01%Current
KYMR
Kymera Therapeutics, Inc.
65/10043/10087/10060/1001.3363.12%KURA vs KYMR
LGND
Ligand Pharmaceuticals Incorporated
76/10061/10086/10070/1001.2536.55%KURA vs LGND
MAZE
Maze Therapeutics, Inc.
59/10042/10083/10047/1000.4167.20%KURA vs MAZE
MBX
MBX Biosciences, Inc. Common Stock
68/100—71/10050/1001.4277.34%KURA vs MBX
Pairwise Compare links: KYMR · LGND · MAZE · MBXKURA vs KYMRKURA vs LGNDKURA vs MAZEKURA vs MBXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a KURA stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for KURA: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-2.35
As of Nov 13, 2026
Revenue growth
10.07%
Gross margin
98.45%
Current debt / equity
1.44
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$22.84M
Quarter net income
-$70.22M
Quarter free cash flow
-$54.89M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
37.1
MACD
-0.79

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
39/100
Beta
1.33
Annual volatility
63.01%
Max drawdown
-49.96%

KURA Stock FAQ

What is KURA stock price today?

Kura Oncology, Inc.'s current stock price is $7.77. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is KURA bullish or bearish right now?

KURA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is KURA's market cap?

KURA's market cap is $697.88M based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is KURA's current P/E ratio?

KURA's current P/E ratio is -2.35 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is KURA's RSI?

KURA's 14-day RSI is 37.1 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is KURA above its 50-day and 200-day moving averages?

KURA is -23.59% from its 50-day SMA and -20.51% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is KURA's next earnings date?

KURA's next earnings date is currently listed as Mar 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does KURA pay a dividend?

KURA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.